ZA202108094B - Mirikizumab for use in a method of treating crohn's disease - Google Patents

Mirikizumab for use in a method of treating crohn's disease

Info

Publication number
ZA202108094B
ZA202108094B ZA2021/08094A ZA202108094A ZA202108094B ZA 202108094 B ZA202108094 B ZA 202108094B ZA 2021/08094 A ZA2021/08094 A ZA 2021/08094A ZA 202108094 A ZA202108094 A ZA 202108094A ZA 202108094 B ZA202108094 B ZA 202108094B
Authority
ZA
South Africa
Prior art keywords
disease
mirikizumab
treating crohn
treatment
crohn
Prior art date
Application number
ZA2021/08094A
Other languages
English (en)
Inventor
Stuart William Friedrich
Paul Frederick Pollack
Jay Lawrence Tuttle
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA202108094B publication Critical patent/ZA202108094B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
ZA2021/08094A 2019-04-22 2021-10-21 Mirikizumab for use in a method of treating crohn's disease ZA202108094B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962836910P 2019-04-22 2019-04-22
PCT/US2020/028273 WO2020219314A1 (en) 2019-04-22 2020-04-15 Mirikizumab for use in a method of treating crohn's disease

Publications (1)

Publication Number Publication Date
ZA202108094B true ZA202108094B (en) 2025-05-28

Family

ID=70554215

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/08094A ZA202108094B (en) 2019-04-22 2021-10-21 Mirikizumab for use in a method of treating crohn's disease

Country Status (17)

Country Link
US (1) US20220040299A1 (enExample)
EP (1) EP3958897A1 (enExample)
JP (3) JP7297930B2 (enExample)
KR (2) KR20250153865A (enExample)
CN (2) CN119700968A (enExample)
AU (2) AU2020263238C1 (enExample)
BR (1) BR112021018930A2 (enExample)
CA (1) CA3134587A1 (enExample)
EA (1) EA202192532A1 (enExample)
IL (2) IL286818B1 (enExample)
MA (1) MA55756A (enExample)
MX (1) MX2021012848A (enExample)
SG (1) SG11202110619XA (enExample)
TW (2) TWI850365B (enExample)
UA (1) UA128657C2 (enExample)
WO (1) WO2020219314A1 (enExample)
ZA (1) ZA202108094B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
KR20220066831A (ko) 2020-11-16 2022-05-24 엔브이에이치코리아(주) 습기경화형 접착제를 이용한 헤드라이닝 제조방법 및 이에 의해 제조되는 헤드라이닝

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20140049B1 (ar) 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
EP3693007A1 (en) 2013-03-15 2020-08-12 Amgen, Inc Methods for treating crohn's disease using an anti-il23 antibody
TWI811716B (zh) * 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
AU2017312049A1 (en) * 2016-08-19 2019-02-21 Janssen Biotech, Inc. Methods of treating Crohn's Disease with an anti-NKG2D antibody
KR20200037258A (ko) * 2017-07-10 2020-04-08 람밤 메드-테크 엘티디. 생물학적 약물로 치료받은 피험자에서 중화 항체 수준 평가용 분석법 및 맞춤 의료에서 이의 사용
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法

Also Published As

Publication number Publication date
CN119700968A (zh) 2025-03-28
JP2022530397A (ja) 2022-06-29
JP7761614B2 (ja) 2025-10-28
AU2020263238C1 (en) 2024-02-22
KR20210142704A (ko) 2021-11-25
AU2023265759A1 (en) 2023-12-07
TW202103734A (zh) 2021-02-01
US20220040299A1 (en) 2022-02-10
BR112021018930A2 (pt) 2022-01-18
CA3134587A1 (en) 2020-10-29
UA128657C2 (uk) 2024-09-18
IL324048A (en) 2025-12-01
CN113677366A (zh) 2021-11-19
EP3958897A1 (en) 2022-03-02
WO2020219314A1 (en) 2020-10-29
JP7297930B2 (ja) 2023-06-26
EA202192532A1 (ru) 2022-01-21
AU2020263238A1 (en) 2021-11-04
NZ781127A (en) 2025-06-27
IL286818A (en) 2021-10-31
AU2020263238B2 (en) 2023-08-17
SG11202110619XA (en) 2021-11-29
TWI850365B (zh) 2024-08-01
JP2023116680A (ja) 2023-08-22
IL286818B1 (en) 2025-11-01
JP2025148449A (ja) 2025-10-07
MX2021012848A (es) 2021-12-10
KR102869852B1 (ko) 2025-10-14
KR20250153865A (ko) 2025-10-27
TW202515610A (zh) 2025-04-16
MA55756A (fr) 2022-03-02

Similar Documents

Publication Publication Date Title
ZA202005388B (en) Methods of treating ulcerative colitis
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2019005594A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia.
MX2018005107A (es) Composiciones y metodos para la terapia relacionada con la microbiota fecal.
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
JOP20220092A1 (ar) جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MY186977A (en) Tetrasubstituted alkene compounds and their use
MX2020013557A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
MX2018011054A (es) Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3.
ZA202004594B (en) Use of tradipitant in motion sickness
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2021008081A (es) Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa.
PH12021551365A1 (en) Compositions and methods for treating and preventing amyotrophic lateral sclerosis
ZA202108094B (en) Mirikizumab for use in a method of treating crohn's disease
EP4371611A3 (en) Regimens and methods of treating multiple sclerosis using ofatumumab
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
EA202193276A1 (ru) Способы лечения холангиокарциномы
MY207627A (en) Methods of treating psoriasis
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
GEAP202315302A (en) METHOD FOR TREATING TNFα-RELATED DISEASE
MX2019004200A (es) Terapia de combinacion.
WO2019236747A3 (en) Cyclic peptide compounds and methods of use thereof